A retrospective survey of the quality of reports and their correlates among randomized controlled trials of immunotherapy for Guillain-Barré syndrome

Immunotherapy

Volumn 5, Issue 8, 2013, Pages 829-836

  Lu, Liming ^a   Luo, Gaoquan ^b   Xiao, Fang ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CONSORT Statement; Guillain Barr syndrome; immunotherapy; quality of reporting; randomized controlled trial

Indexed keywords

CORTICOSTEROID;

ARTICLE; CORTICOSTEROID THERAPY; FUNDING; GUILLAIN BARRE SYNDROME; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; LANGUAGE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ADRENAL CORTEX HORMONES; ADULT; CHILD; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; PHARMACOVIGILANCE; PLASMA EXCHANGE; QUALITY IMPROVEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84881269096     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.75     Document Type: Article

References (46)

1. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 366(9497), 1653-1666 (2005
2. Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr. Opin. Neurol. 14(5), 605-613 (2001
3. Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Neurology 53(8), 1648-1654 (1999
4. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J. Neurol. Neurosurg. Psychiatry 64(1), 74-77 (1998
5. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 1, CD002063 (2006
6. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 2(8099), 1100 (1978
7. The Guillain-Barré syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35(8), 1096-1104 (1985
8. Osterman PO, Fagius J, Lundemo G et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2(8415), 1296-1299 (1984
9. Plasma exchange in Guillain-Barré syndrome: One-year follow-up. French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Ann. Neurol. 32(1), 94-97 (1992
10. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Ann. Neurol. 41(3), 298-306 (1997
11. The utility of therapeutic plasmapheresis for neurological disorders. Natl Inst. Health Consens. Dev. Conf. Consens. Statement 6(4), 1-7 (1986
12. Kleyweg RP, van der Meche FG, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 38(10), 1639-1641 (1988
13. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré study group. N. Engl. J. Med. 326(17), 1123-1129 (1992
14. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. The Dutch Guillain-Barré study group. Ann. Neurol. 35(6), 749-752 (1994
15. van Koningsveld R, Schmitz PI, Meche FG et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: Randomised trial. Lancet 363(9404), 192-196 (2004
16. Li JY, Zhang YF, Smith GS et al. Quality of reporting of randomized clinical trials in tai chi interventions -A systematic review. Evid. Based Complement Alternat. Med. 2011, 383245 (2011
17. Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 340, c869 (2010
18. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27(Suppl.), S21-S24 (1990
19. Diallo S, Cour F, Josephson A et al. Evaluating single-incision slings in female stress urinary incontinence: The usefulness of the CONSORT statement criteria. Urology 80(3), 535-541 (2012
20. Toulmonde M, Bellera C, Mathoulin-Pelissier S, Debled M, Bui B, Italiano A. Quality of randomized controlled trials reporting in the treatment of sarcomas. J. Clin. Oncol. 29(9), 1204-1209 (2011
21. Rios LP, Odueyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. J. Clin. Endocrinol. Metab. 93(10), 3810-3816 (2008
22. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273(5), 408-412 (1995
23. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 287(21), 2801-2804 (2002
24. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-Analyses. Ann. Intern. Med. 135(11), 982-989 (2001
25. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319(7211), 670-674 (1999
26. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré syndrome steroid trial group. Lancet 341(8845), 586-590 (1993
27. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Lancet 349(9047), 225-230 (1997
28. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46(1), 100-103 (1996
29. Diener HC, Haupt WF, Kloss TM et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur. Neurol. 46(2), 107-109 (2001
30. DiMario FJ Jr. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré syndrome: A randomized trial. Pediatrics 116(1), 226-228 (2005
31. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: A randomized study. Crit. Care 15(4), R164 (2011
32. Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand. J. Infect. Dis. 27(3), 241-243 (1995
33. Gürses NUS, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand. J. Infect. Dis. 27(3), 241-243 (1995
34. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J. Neurol. Sci. 137(2), 145-149 (1996
35. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: A randomized trial. Pediatrics 116(1), 8-14 (2005
36. Morosetti M, Meloni C, Taccone Gallucci M et al. Plasmapheresis versus plasma perfusion in acute Guillain-Barré syndrome. ASAIO J. 40(3), M638-M642 (1994
37. Kyoichi N, Katsuhiko H, Takamichi H et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol. Ther. 18, 69-81 (2001
38. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC; French Guillain-Barré Syndrome Cooperative G. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J. Neurol. Neurosurg. Psychiatry 71(2), 235-238 (2001
39. Singh NK. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome? J. Assoc. Physicians India 44(1), 22-24 (1996
40. Wollinsky KH, Hulser PJ, Brinkmeier H et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: A randomized clinical trial. Neurology 57(5), 774-780 (2001
41. Zhang X, Xia J, Ye H. [Effect of tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barré syndrome]. Zhongguo Zhong Xi Yi Jie He Za Zhi 20(5), 332-334 (2000
42. Egger M, Juni P, Bartlett C, Group C. Value of flow diagrams in reports of randomized controlled trials. JAMA 285(15), 1996-1999 (2001
43. Altman DG. Adjustment for covariate imbalance. In: Encylopedia of Biostatistics. Armitage F and Colton T (Eds). Wiley, Chichester, UK (1998
44. Uetani K, Nakayama T, Ikai H, Yonemoto N, Moher D. Quality of reports on randomized controlled trials conducted in Japan: Evaluation of adherence to the CONSORT Statement. Intern. Med. 48(5), 307-313 (2009
45. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 272(2), 125-128 (1994
46. Wang R, Feng A, Sun W, Wen Z. Intravenous immunoglobulin therapy in children with Guillain-Barré syndrome. J. Appl. Clin. Pediatrics 16(4), 223-224 (2001